IN a previous paper the excretion of oestrogens, 17-oxosteroids and 17-oxogenic steroids by men with untreated prostatic cancer was compared with that of controls of the same age, and the effects of treatment by synthetic oestrogens or by castration were briefly described (Bulbrook, Franks and Greenwood, 1959 Chemical methods used are as previously described (Bulbrook, Franks and Greenwood, 1959) . The effects of synthetic oestrogen treatment on the urinary oestrogen excretion are given for oestrone and oestriol only since the oestradiol-17, fraction cannot be measured accurately in urine from these patients. Intravenous diethyl stilboestrol phosphate also interferes with the measurement of oestrone and in one case where this compound was given only oestriol values are reported.
treatment. The mean hormone excretion in the pre-treatment period-the control level-has been used as the baseline for comparing subsequent hormone determinations during treatment. Age refers to that at operation or at the start of treatment. a. Castration: its effects on the clinical state and on the excretion of oestrone, oestradiol17fl, oestriol, 17-oxosteroids and 17-oxogenic steroids. (Group of three patients)
Patient No. 1, aged 66 years, was admitted with incontinence and supra-pubic pain. The prostate was clinically malignant and a prostatic smear contained malignant cells. The serum acid phosphatase (formalin inactivated) was 3.0 units.
There were no skeletal metastases on X-ray examination. After a control period of 9 days the patient was treated by castration and per-urethral resection. The resected tissue contained areas of anaplastic carcinoma. The changes in hormone excretion are shown in Fig. 1 . In the immediate post-operative period there was a marked rise in excretion of all three groups of steroids measured. This phenomenon has been frequently observed to follow operation and is probably due to an adrenal cortical reaction to stress. After this initial rise the amounts of excreted oestrogens and 17-oxosteroids fell progressively to pre-operative levels. Oestrogens were not detected in the urine 14 weeks after operation, and the 17-oxosteroid excretion was very low. Clinically there was a marked improvement with complete freedom from symptoms. Over the period from 33 to 65 weeks after operation, oestrogen was again detectable in the urine increasing to pre-operative levels and accompanied by an increase in 17-oxosteroid secretion. This period was characterised by the appearance and subsequent development of metastases in the pelvis and spine. When the patient complained of pain, 72 weeks after castration, stilboestrol was given. This was followed by rapid objective and subjective improvement and a second fall in oestrogen and 17-oxosteroid levels. The excretion of 17-oxogenic steroids remained unchanged throughout the period of observation.
Patient No. 2, aged 70 years, was admitted complaining of urinary difficulty for 6 months. Clinically the prostate was malignant and prostatic smears contained malignant cells (confirmed by later biopsy). The serum acid phosphatase was 1-5 units. There were no skeletal metastases on X-ray examination. The patient was castrated and the post-operative hormonal changes are shown in Fig. 2 .
A transient rise in oestrogen excretion in the immediate post-operative period was followed by a fall to below the pre-operative levels. Later specimens obtained during follow-up showed a return of excretion to pre-operative values. The 17-oxosteroid levels showed no significant change at operation or in the following 46 weeks, whereas the 17-oxogenic steroids showed a slow fall after operation to low levels but with one exceptionally high value. Clinically the operation resulted in the disappearance of urinary symptoms and an arrest in the tumour growth up to 44 weeks. The re-appearance of mild urinary symptoms was noted some 32 weeks after the return of oestrogen excretion to pre-operative levels, and on exami- A per-urethral biopsy showed one small nodule of prostatic carcinoma of low grade. Serum acid phosphatase was 1.1 units. Fifteen months later there was haematuria and the prostate (per rectum) was hard and clinically malignant. The urine deposit contained malignant cells. TACE (12 mg. t.d.s.) was administered and over the first 10 days of treatment no change occurred in hormone excretion. At the first follow-up (11 weeks) the patient was well. At this stage, oestrogen excretion had fallen to zero; 17-oxosteroid and 17-oxogenic steroid levels were depressed. Serum acid phosphatase was 1-5 units.
At the second follow-up (34 weeks), oestrogen was again detected in the urine but at a level well below that of the control period. 17-Oxosteroids and 17-oxogenic steroids were lower than at the previous follow-up. At the third follow-up (27 weeks), 17-oxogenic steroid excretion was markedly depressed but rose to pre-treatment levels at 52 weeks and remained so at 85 weeks. The serum acid phosphatase was normal throughout and the patient has remained in remission. In this series synthetic oestrogens had little or no immediate effect on 17-oxosteroid excretion. In four cases this fraction was depressed (No. 5, 6, 7 and 8), and a minimum of 7 days treatment was required for the effect to become manifest. In the fifth case (No. 4), 17-oxosteroid excretion was unchanged over 102 weeks of treatment. In only two of the five cases was there a return to normal levels.
With the exception of Case No. 4, 17-oxogenic steroid excretion was depressed by treatment, the effect taking a week to become apparent. This fall was maintained over a long period in three patients (No. 5, 6 and 7) but in the remaining case (No. 8), excretion had risen to the control level by 52 weeks.
Oestrogen: androgen ratios
The pre-treatment oestrogen levels for the 8 patients described were divided by the 17-oxosteroid levels and the ratios obtained compared with those obtained from the data for normal controls without prostatic cancer (Bulbrook, Franks and Greenwood, 1959) . There was no significant difference between the mean ratios for the two groups (0.0011 and 0.0019 respectively). In both groups the daily oestrogen/17-oxosteroid ratio was fairly constant for a particular subject but there was a 20-fold variation between individual subjects.
DISCUSSION
Changes in excretion after treatment In a previous paper (Bulbrook, Franks and Greenwood, 1959) we have shown that the excretion of oestrogens, 17-oxosteroids and 17-oxogenic steroids in men with untreated prostatic cancer does not differ significantly from that found in patients of a similar age without clinical cancer. However after treatment with synthetic oestrogens or by castration there is a temporary fall in the excretion of one or more of the three groups of hormones measured, followed by a rise to pretreatment levels. This biphasic response is shown most clearly by the oestrogens. The time taken for these changes to occur varies from patient to patient. Clinical improvement tends to precede marked decrease in hormone excretion, but the period of lowest hormone excretion was generally associated with retardation of tumour growth. The increase in hormone excretion to control levels again generally preceded clinical signs of renewed tumour growth.
When the results are considered in detail several further points arise. There is little doubt about the biphasic response to oestrogen treatment or to castration; the fall and subsequent rise in excretion of at least one of the three groups of hormones is generally marked. There are two other effects which are so slight that there must be some doubt as to their general occurrence. The first of these is the slight and transient rise in 17-oxosteroids, 17-oxogenic steroids or oestrogens which sometimes occurs in the first two or three days after treatment with synthetic oestrogen is started. In the 17-oxosteroid fraction this occurred in one patient, in the 17-oxogenic steroids and the oestrogens in 2 patients. The subsequent fall in excretion was clearly manifest by about the seventh day of treatment.
The second minor effect was seen in three cases (2, 5 and 6), one a castrate, the others treated with stilboestrol. Hormone excretion fell, rose again to pretreatment levels and then dropped again, over a period of several months. Burt, Finney and Scott (1957) found a similar change in 3 patients treated by castration. It is possible that this might have been found in other cases if specimens had been collected at shorter intervals of time. These changes did not seem to be associated with changes in the clinical state and their significance is uncertain.
The effect of castration on oestrogen excretion.-In all three cases there was a rise in excretion in the immediate post-operative period which is thought to be an adrenal cortical reaction to operative stress. A similar rise occurs after oophorectomy in the female (Bulbrook and Greenwood, 1957) . Oestrogens are thought to be mainly produced by the testes in man but in two of the three cases (No. 1 and 3) castration had virtually no immediate effect on oestrogen excretion, suggesting that this hormone was being produced in some other organ, presumably the adrenal. Nevertheless, over the following three months, oestrogen excretion slowly declined. In Case 2 however oestrogen excretion fell to roughly one-third of the pre-operative level within 14 days and there was no evidence of a further fall at subsequent examinations.
Variability of response to treatment.-The pre-treatment hormone levels found in this small series differed widely from patient to patient. Oestrogen excretion varied eight-fold between the patients, 17-oxosteroids three-fold and 17-oxogenic steroids four-fold. Although the general pattern of response to treatment was similar, the time taken for the changes to occur and the absolute amounts of hormones excreted during treatment were equally varied. This may be due to differences in response, from patient to patient, to a given dose of a synthetic oestrogen. It is possible that the most effective dose varies as widely from patient to patient as insulin requirements in diabetics. The variation in response to hormones may be genetically determined. This is well known in experimental animals and it is likely that it also occurs in man.
Not only does treatment elicit a variable response from patient to patient but in each, the three groups of hormones measured also vary independently. The oestrogens, 17-oxosteroids and 17-oxogenic steroids do not necessarily rise and fall together and in some cases only one or two of the three groups of hormones show an effect. It is probable that relative changes in excretion in the individual patient may be of greater significance than the absolute levels.
Hormone excretion and clinical state.-The similarity of oestrogen: androgen ratio in patients with and without clinical cancer suggests that a disturbance of the endogenous production of these hormones is not associated with the development of clinical prostatic cancer. However, there seems to be a rough correlation in this group of patients between the period of clinical improvement and lowered hormone excretion after treatment, particularly as far as the urinary oestrogens are concerned. This association may be fortuitous and was not invariably found in another series of cases which had been treated with synthetic oestrogens for more than five years (Bulbrook, Franks and Greenwood, 1959) . All the hormones measured in this study are produced in response to stimulation by trophic pituitary hormones. If the primary endocrine disturbance associated with the growth of prostatic tumours is hypophyseal, the changes observed in steroid hormone excretion may not reflect the pituitary changes very accurately.
Another possibility which must be considered is that there is a level, perhaps varying from patient to patient, above which tumour growth is maximally stimulated. In this case the absolute amount of hormones produced would not necessarily be directly proportional to the growth activity.
Possible sources of error
In any clinical investigation a number of possible sources of error must be recognised. These include amongst others the accuracy of the original diagnosis, inadequate sample size and conscious or unconscious selection of cases. In this investigation the clinical diagnosis has been confirmed microscopically in all cases but it must be realised that the microscopy gives no guide to the biological malignancy of the tumours (Franks, Fergusson and Murnaghan, 1958) . In addition only a small number of patients has been studied but the findings are in general agreement with similar investigations. In this group there has been some selection of patients, in that the severely ill patient, with urinary obstruction or gross infection was unsuitable for investigation. Similarly, patients with small "early "tumours were often treated as out-patients and not admitted to hospital.
The patients in this short-term group are therefore those with moderately severe disease but without gross urinary disturbance.
Summary and conclu8ions
The urinary excretion of oestrogens, 17-oxosteroids and 17-oxogenic steroids was measured in 8 patients with prostatic cancer, before and at intervals during treatment by castration (3 cases) or synthetic oestrogens (5 cases). The excretion of these hormones is depressed by such treatment but in most cases there is a later rise to pretreatment levels. This biphasic response is shown most clearly by the oestrogens. Objective regression of tumour growth in these cases, is associated with depression of hormone excretion. The later rise in excretion is generally followed by renewed tumour growth.
There is a wide variation in the response to treatment from patient to patient and each of the three groups of hormones measured may vary independently.
The changes measured may reflect changes in pituitary function. This may be the basic endocrine factor.involved. 
